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Background: Antibiotic combination therapy for Helicobacter pylori eradication must be adapted to local resistance
patterns, but the epidemiology of H. pylori resistance to antibiotics is poorly documented in Africa. The aim was to
determine the antibiotic resistance rates, as well as the associated molecular mechanisms, of strains isolated in
Dakar, Senegal.
Methods: One hundred and eight H. pylori strains were isolated between 2007 and 2009 from 108 patients
presenting with upper abdominal pain to the Gastroenterology Department of Le Dantec Hospital. Antimicrobial
susceptibility testing was performed for amoxicillin, clarithromycin, metronidazole, levofloxacin and tetracyclin using
the E-test method. Mutations in the 23S rRNA gene of clarithromycin-resistant strains and in gyrA and gyrB of
levofloxacin-resistant strains were investigated.
Results: Isolates were characterized by no resistance to amoxicillin (0%), tetracycline (0%), and very low rate of
resistance to clarithromycin (1%), but a high rate of resistance to metronidazole (85%). The clarithromycin-resistant
strain displayed the A2143G mutation. A worrying rate of levofloxacin resistance was detected (15%). N87I and
D91N were the most common mutations in the quinolone-resistance-determining region of gyrA.
Conclusions: The first-line empirical regimen for H. pylori eradication in Senegal should include clarithromycin.
Increasing rates of fluoroquinolone resistance detected should discourage the use of levofloxacin-containing
regimens without prior antimicrobial susceptibility testing.
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Helicobacter pylori is associated with severe gastroduo-
denal disorders, including peptic ulcer disease, gastric
adenocarcinoma, and gastric mucosa-associated lymph-
oid tissue lymphoma [1]. About 15% of infected people
will develop a peptic ulcer and 1-3% a gastric malig-
nancy during their lifetime. All guidelines worldwide
recommend the eradication of H. pylori in symptomatic
patients [2]. This treatment commonly consists of triple-
agent therapy with a double-dose proton pump inhibitor
(PPI) and two antibiotics chosen from amoxicillin,* Correspondence: sbreurec@gmail.com
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reproduction in any medium, provided the orclarithromycin and metronidazole, for 7 to 14 days,
yielding an eradication rate ranging from 70% to 80%.
Antibiotic resistance is the main cause of treatment fail-
ure. In particular, clarithromycin resistance can lead to a
70% decrease in efficacy [3]. Bismuth-containing four-
drug regimens or, if the latter are unavailable, sequential
treatment or a non-bismuth four-drug regimen, is recom-
mended for first-line empirical treatment in areas of high
clarithromycin resistance. Levofloxacin-containing triple
therapy should be preferred when these treatments fail
[2]. Clarithromycin resistance is mainly due to point
mutations in the 23S ribosomal RNA (rRNA) gene.
A2143G and A2142G are the most frequent mutations
[4]. Resistance to quinolones is mainly due to mutations
in the quinolone-resistance-determining region (QRDR)d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gyrase, at codons 86, 87, 88 and 91 [3]. Very few data are
available on H. pylori resistance to antibiotics in Africa
[5-9]. Here we examined the prevalence of H. pylori resist-
ance to antibiotics, and the associated molecular mechan-
isms, in symptomatic African patients in Dakar (Senegal).
Methods
Study population
A total of 108 H. pylori strains were isolated between
2007 and 2009 from 108 patients presenting with upper
abdominal pain to the Gastroenterology Department of
Le Dantec Hospital (Dakar, Senegal). Median age was
42.0 years (mean 45.3 years; interquartile range (IQR)
31.0–56.6 years; range, 18–93 years), and 55% of the
patients (n=59) were males. The predominant ethnic
groups were Wolof (37%), Fulani (16%), and Serer (14%),
in keeping with the ethnic distribution in Senegal. On
the basis of endoscopic findings, 30 patients had gastritis
only, 63 had ulcerated lesions, and 15 had suspicion of
neoplasia. All cases of suspected neoplasia were histolo-
gically confirmed as gastric cancer.
No patient had previously received anti-H. pylori ther-
apy. Three biopsy samples were taken from the antrum
and three from the fundus during upper gastrointestinal
endoscopy. One biopsy sample from each site was cul-
tured for H. pylori isolation, and the other four were
fixed and processed for histological analysis. All endo-
scopes and accessory devices were decontaminated after
every endoscopy, according to local written procedures.
On the basis of endoscopic findings, patients were classi-
fied as having gastritis only, ulcerated lesion, or sus-
picion of neoplasia. Written informed consent was
obtained from all the patients and the study protocol
was approved by the Senegalese national ethics
committee.
Histology
Histopathological diagnoses were performed according
to the updated Sydney System [10], and to the Vienna
classification for dysplasia [11].
H. Pylori culture and antimicrobial susceptibility testing
H. pylori culture was performed using Columbia agar
plates with 10% (v/v) defibrinated horse blood and an H.
pylori selective antibiotic supplement (Oxoid, Basing-
stoke, UK) containing vancomycin (10 mg/L), cefsulodin
(5 mg/L), trimethoprim (5 mg/L) and amphotericin B (5
mg/L). The plates were incubated for up to 10 days at
37°C in microaerophilic conditions (GENbag, Biomer-
ieux). H. pylori was identified by colony and microscopic
morphology, and by positive urease, catalase and oxidase
tests. Antibiotic susceptibility was determined from a
mixture of colonies from antrum and fundus sampleswith the E-test method (Biomérieux, Marcy l’Etoile,
France) using Mueller–Hinton agar supplemented with
10% horse blood as previously described [12]. According
to CLSI breakpoints [13], the resistance breakpoints
were 0.5 mg/L for amoxicillin (EUCAST [14], ≥ 0.12
mg/L), 1 mg/L for clarithromycin (EUCAST, ≥ 0.5 mg/
L), 2 mg/L for tetracycline (EUCAST, ≥ 1 mg/L), 1 mg/L
for levofloxacin (similar to the EUCAST value), and 8
mg/L for metronidazole (similar to the EUCAST value).DNA extraction and mutation analysis of the 23S rRNA,
gyrA and gyrB genes
Genomic DNA was extracted with the QIAmp kit
(Qiagen, Courtaboeuf, France). The QRDR region of
gyrA was sequenced using primers gyrA5 and gyrA2 in
levofloxacin-resistant strains [4]. If no mutation was
detected, the full-length gyrA and gyrB genes were
sequenced as previously described [4] and were com-
pared with the sequences from five randomly selected
levofloxacin-sensitive isolates. Point mutations in the
23S rRNA gene were investigated by using Scorpion
PCR in strains resistant to clarithromycin [12].Statistical analysis
The chi-square test for trend was used to compare rates
of resistance to antibiotics during the study period.
P values of ≤0.05 were considered statistically significant.
All analyses were performed by using STATA 12.0 (Stata
Corporation, College Station, Tex.).Results
Patients and antibiotic susceptibility testing
One hundred eight H. pylori isolates were cultured from
gastric biopsy samples obtained from volunteers during
gastroduodenal endoscopy at Le Dantec Hospital (Dakar,
Senegal) between 2007 and 2009.
According to EUCAST and CLSI breakpoints, all iso-
lates tested were susceptible to amoxicillin (MIC range,
<0.016-0.047 mg/L), tetracycline (MIC range, <0.016-
0.75 mg/L) and clarithromycin (MIC range, <0.016-0.47
mg/L), except for one clarithromycin-resistant strain
(MIC>256 mg/l). The isolates were characterized by high
rates of resistance to metronidazole (MIC range, <0.016-
>256 mg/L) (85%, n=92) and intermediate rates of sus-
ceptibility to levofloxacin ((MIC range, <0.002->32 mg/
L) (85%, n=92) (Table 1). The clarithromycin-resistant
strain was resistant to both levofloxacin (MIC>32 mg/L)
and metronidazole (MIC>256 mg/L). Twelve of the 16
levofloxacin-resistant strains were also resistant to
metronidazole. No significant difference in the preva-
lence of resistance to antibiotics was observed during
the study period (P>0.5).
Table 1 Resistance to antibiotics of H. pylori isolates in
Dakar, Senegal, from 2007 to 2009
n (%) MIC (mg/L)
Median Range
Amoxicillin 0 <0.016 <0.016-0.047
Tetracycline 0 <0.016 <0.016-0.75
Levofloxacin 16 (15) 0,125 <0.002->32
Metronidazole 92 (85) >256 <0.016->256
Clarithromycin 1 (1) <0.016 <0.016->256
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resistant strain and of gyrA and gyrB in levofloxacin-
resistant strains
Only one strain was resistant to clarithromycin. Resist-
ance was due to a point mutation at nucleotide position
2143 (A2143G) of the 23S rRNA gene. Among the 16
levofloxacin-resistant strains, 13 harbored a specific
mutation in the QRDR of the gyrA gene, previously
reported to confer resistance to fluoroquinolones. The
amino acid positions concerned were 87 and 91: N87I,
n=7 (MICs>32 mg/l); D91N, n=4 (MIC range, 4–16 mg/
l); D91G, n=1 (MIC=2 mg/l); D91Y, n=1 (MIC>32 mg/l).
As three strains with MICs of 8 mg/l displayed no muta-
tions in the QRDR of gyrA, the entire gyrA and gyrB
genes of these strains were sequenced. No mutation was
detected.Discussion
Antibiotic resistance is the most important factor re-
sponsible for the declining success rate of H. pylori
eradication therapy. Surveillance of H. pylori antibiotic
resistance is mandatory in order to adapt the antibiotic
combination to local resistance patterns.
The rates of H. pylori resistance to amoxicillin (0%)
and metronidazole (85%) observed in Senegal were in
keeping with those reported in this country in 1999–
2000 (0% and 90%, respectively) [8]. In contrast, re-
sistance to levofloxacin rose from 0% in 1999–2000 to
15% in 2007–2008, mirroring the situation in several
European and Asian countries, with increases from 3%
in 1999 to 15% in 2004 in France, from 11% in 2003 to
22% in 2005 in Germany, from 3% in 1998 to 12% in
2003 in Taiwan, and from 0% in 1987 to 33% in 2003 in
South Korea [15-19]. This probably reflects the increas-
ing use of quinolones in these countries [20,21], high-
lighting the importance of appropriate use of this class
of antibiotics to limit the development of antimicrobial
resistance. Interestingly, a significant increase in cipro-
floxacin resistance has also been observed in Escherichia
coli isolates from Senegalese patients with community-
acquired urinary tract infections (10% in 2004, 22% in
2006) [22].The lack of resistance to amoxicillin and tetracycline
in this study indicates that H. pylori resistance to these
agents is probably exceptional (0 to 1.3%) and low (0 to
4.4%), respectively, whatever the continent [21,23]. The
high prevalence of resistance to these antibiotics
observed in some developing and emerging countries
probably reflects inadequate laboratory facilities [5-7,9]
(e.g. 6% in Ethiopia, 6.6% in Bangladesh, 39.0% in Brazil,
59% in Iran for resistance to amoxicillin; 9.0% in Brazil,
15.0% in Bangladesh, 27.0% in Chile for resistance to tet-
racyclin). In our study, only one strain was resistant to
clarithromycin (MIC>256 mg/l), likely reflecting low
macrolide consumption, although no data on antibiotic
consumption for clarithromycin but also erythromycin
and azithromycin are available for Senegal. This resist-
ance was due to a point mutation at nucleotide position
2143 (A2143G) of the 23S rRNA gene, a well-known
mutation described worldwide. Resistance to clarithro-
mycin is increasing in most countries in Central, West-
ern and Southern Europe, as well as in East Asia, and
has now reached more than 20% in these areas.
Clarithromycin-containing regimens should thus be
recommended for first-line empirical H. pylori eradica-
tion therapy.
The prevalence of resistance to levofloxacin was 15%
in Senegal. In the 16 levofloxacin-resistant strains, N87I
and D91N were the most common mutations in the
QRDR region of gyrA. The major mutation (N87I) has
been detected sporadically worldwide [16], indicating
that local founder effects have resulted in local propaga-
tion of resistant clones. D91N is a well-known mutation
detected worldwide [4]. As three strains with levofloxa-
cin MICs of 8 mg/l displayed no mutations in the QRDR
of gyrA, we sequenced the entire gyrA and gyrB genes of
these strains but found no mutations. This points to the
presence of another mechanism such as reduced drug
accumulation [4]. The Maastricht IV/Florence Consen-
sus Report recommends that empirical use of levofloxa-
cin should be abandoned when the prevalence of
resistance reaches 15–20% [2]. Levofloxacin-containing
therapy should therefore only be used in Senegal if com-
patible with the antimicrobial resistance pattern of the
strain.
The worldwide prevalence of resistance to metronida-
zole ranges from 20–40% in Europe and the USA, to
50–80% in developing countries, Iran, India and Egypt
displaying the highest rates of resistance (80 to 100%)
[6,21,24,25]. Metronidazole is used extensively to treat
parasitic diseases in tropical countries, which probably
explains the higher prevalence of resistance to this drug.
Although standard metronidazole susceptibility testing
lacks reproducibility, trends of low, medium, or high
prevalence rates observed at a population level seem real.
Then, metronidazole-containing triple therapy should not
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tion therapy. It should be used within bismuth-based
quadruple regimen [26] or sequential treatment for 14
days [27].
Conclusions
Even though our findings may not be representative of the
overall situation, it should be noted that the study took
place in one of the main tertiary hospitals in Senegal, with a
large geographical origin of the patients attending the study
health facility. The data reported here are particularly im-
portant, given the difficulty of carrying out such studies in
countries with inadequate healthcare systems and the need
to choose antibiotic combinations for H. pylori eradication
according to local resistance patterns. Clarithromycin-
containing regimens should be recommended for first-line
empirical H. pylori eradication therapy. Increasing rates of
fluoroquinolone resistance detected in Senegal should dis-
courage the use of levofloxacin-containing regimens with-
out prior antimicrobial susceptibility testing. N87I and
D91N were the most common mutations in the H. pylori
gyrA QRDR.
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